FLT3 Protein, Human (T227M, HEK293, His)
Based on 1 Customer Validation
FLT3 is a tyrosine-protein kinase receptor that regulates differentiation, proliferation, and survival of hematopoietic progenitor cells and dendritic cells. It phosphorylates downstream effectors such as SHC1 and AKT1, activating signaling cascades involving MTOR, RAS, and MAP kinases. FLT3 Protein, Human (T227M, HEK293, His) is the recombinant human-derived FLT3 protein, expressed by HEK293 , with C-His labeled tag.
- Species: Human
- Source: HEK293
-
Storage:Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Biological Activity
Description
FLT3 is a tyrosine-protein kinase receptor that regulates differentiation, proliferation, and survival of hematopoietic progenitor cells and dendritic cells. It phosphorylates downstream effectors such as SHC1 and AKT1, activating signaling cascades involving MTOR, RAS, and MAP kinases. FLT3 Protein, Human (T227M, HEK293, His) is the recombinant human-derived FLT3 protein, expressed by HEK293 , with C-His labeled tag.
Background
FLT3, a tyrosine-protein kinase, functions as a cell-surface receptor for the cytokine FLT3LG, exerting regulatory control over the differentiation, proliferation, and survival of hematopoietic progenitor cells and dendritic cells. This receptor facilitates the phosphorylation of various downstream effectors, including SHC1 and AKT1, and activates signaling cascades involving MTOR, RAS, MAPK1/ERK2, and/or MAPK3/ERK1. Moreover, it plays a pivotal role in the phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. While wild-type FLT3 activation leads to modest STAT5A or STAT5B activation, mutations causing constitutive kinase activity result in heightened cell proliferation and resistance to apoptosis, underscoring its role in fostering aberrant signaling pathways.
Verified Bioactivity
1.This product does not contain protein kinase domain.
2.Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human Flt-3 Ligand at 10 μg/mL can bind Biotinylated Human Flt-3. The ED50 for this effect is 0.1-1.0 μg/mL.
3.Loaded Anti-FLT3 Antibody (AGS62P) (HY-P990786) on AHC2 biosensor, can bind FLT3 Protein, Human (T227M, HEK293, His) with an affinity constant of 2.203E-08 M as determined in BLI assay.
4.Loaded Flt-3L-Ig (hum/hum, HY-P991208) on AHC2 biosensor, can bind FLT3 Protein, Human (T227M, HEK293, His) with an affinity constant of 2.041E-08 M as determined in BLI assay.
5.Loaded IMC-EB10 (HY-P991641) on ACH2 biosensor, can bind FLT3 Protein, Human (T227M, HEK293, His) with an affinity constant of 4.903E-07 M as determined in BLI assay.
MCE Validation Data
-
Purity - SDS-PAGE
Purity - SDS-PAGE
-
Bioactivity - ELISA
Bioactivity - ELISA
-
Bioactivity - BLI
Bioactivity - BLI
-
Bioactivity - BLI
Bioactivity - BLI
-
Bioactivity - BLI
Bioactivity - BLI
Technical Parameters
-
Species Human
-
Source HEK293
-
Tag C-10*His
-
Accession
P36888-1 (N27-N541, T227M)
-
Molecular Construction
-
N-term
-
FLT3 (N27-N541, T227M)
Accession # P36888-1 -
His
-
C-term
-
-
Protein Length
Extracellular Domain
-
Synonyms
FLT3; CD135 Antigen; Fms Related Receptor Tyrosine Kinase 3; FLK-2; CD135; Growth Factor Receptor Tyrosine Kinase Type III; STK1; Receptor Protein-Tyrosine Kinase; FLK2; Fms-Related Tyrosine Kinase 3; Fms-Like Tyrosine Kinase 3; Fetal Liver Kinase 2; Rece
-
AA Sequence
NQDLPVIKCVLINHKNNDSSVGKSSSYPMVSESPEDLGCALRPQSSGTVYEAAAVEVDVSASITLQVLVDAPGNISCLWVFKHSSLNCQPHFDLQNRGVVSMVILKMTETQAGEYLLFIQSEATNYTILFTVSIRNTLLYTLRRPYFRKMENQDALVCISESVPEPIVEWVLCDSQGESCKEESPAVVKKEEKVLHELFGMDIRCCARNELGRECTRLFTIDLNQTPQTTLPQLFLKVGEPLWIRCKAVHVNHGFGLTWELENKALEEGNYFEMSTYSTNRTMIRILFAFVSSVARNDTGYYTCSSSKHPSQSALVTIVEKGFINATNSSEDYEIDQYEEFCFSVRFKAYPQIRCTWTFSRKSFPCEQKGLDNGYSISKFCNHKHQPGEYIFHAENDDAQFTKMFTLNIRRKPQVLAEASASQASCFSDGYPLPSWTWKKCSDKSPNCTEEITEGVWNRKANRKVFGQWVSSSTLNMSEAIKGFLVKCCAYNSLGTSCETILLNSPGPFPFIQDN
-
Molecular Weight
Approximately 85-95 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.
-
Glycosylation
Yes
-
Purity
≥ 95%, as determined by reducing SDS-PAGE.
Product Properties
Lyophilized powder.
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4, 8% trehalose.
<1 EU/μg, determined by LAL method.
It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O.
Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Room temperature in continental US; may vary elsewhere.
Documentation
-
Data Sheet (239 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)